Infant developmental delays at well visit encounters in infants exposed to medications for opioid use disorder: buprenorphine or methadone

Chaitali Korgaonkar-Cherala MD, MS

Department of Obstetrics, Gynecology, and Reproductive Medicine Renaissance School of Medicine at Stony Brook University



OUD in Pregnancy

- OUD in pregnancy has effects on neonatal, infant, and childhood health and development
- Treatment of OUD in pregnancy improves perinatal outcomes
- MOUD during pregnancy may have risks for the neonate into childhood

Opioid use disorder (OUD) rose more than 4x among pregnant women from 1999 to 2014.






Ryan, Kimberly, et al. "Opioid Use in Pregnancy: A Review." *Obstetrical and Gynecological Survey*, vol. 78, no. 1, Jan. 2023, https://doi.org/10.1097/OGX.00000000001094.

https://www.cdc.gov/mmwr/volumes/67/wr/mm6731a1.htm

Comparison of Opioid Agonists






Suarez, Elizabeth, et al. "Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy." *New England Journal of Medicine*, Dec. 2022, DOI: 10.1056/NEJMoa2203318.

What is Neonatal Opioid Withdrawal Syndrome (NOWS)?

Signs of neonatal abstinence syndrome (NAS) primarily occur in the neurologic, respiratory, and GI systems.





https://www.myamericannurse.com/caring-for-infants-and-families-affected-by-neonatal-abstinence-syndrome/

MacMillan KDL. Neonatal Abstinence Syndrome: Review of Epidemiology, Care Models, and Current Understanding of Outcomes. Clin Perinatol. 2019 Dec;46(4):817-832. doi: 10.1016/j.clp.2019.08.012. Epub 2019 Aug 14. PMID: 31653310.

Pediatric Developmental Milestones



1 month

2 months

3 months

4-5 years

Stony Brook Medicine

Jennifer M. Zubler, Lisa D. Wiggins, Michelle M. Macias, Toni M. Whitaker, Judith S. Shaw, Jane K. Squires, Julie A. Pajek, Rebecca B. Wolf, Karnesha S. Slaughter, Amber S. Broughton, Krysta L. Gerndt, Bethany J. Mlodoch, Paul H. Lipkin; Evidence-Informed Milestones for Developmental Surveillance Tools. *Pediatrics* March 2022; 149 (3): e2021052138. 10.1542/peds.2021-052138

https://story.motherhood.com.my/blog/children-development-milestones-the-first-five-years/



Evaluation of Developmental Delay at Pediatric Well-Visits

Table 2. Comparison of Parent-Completed Screening Tools for Childhood Developmental Delay

ТооІ	Validated?	Number of items	Sensitivity (%)	Specificity (%)	Age range assessed	Time to complete; time to score*
Ages and Stages Questionnaire, 3rd ed. http://agesandstages.com	Yes ²⁹	40, including 10 parental questions ¹⁸	86 ³⁰	85 ³⁰	One to 66 months ³⁰	10 to 15 minutes; One to three minutes ³⁰
Child Development Review– Parent Questionnaire http://childdevrev.com/ healthcaretools/cdr-parent- questionnaire	Yes ³¹	32 questions; 99 additional items ³¹	68 ³¹	88 ³¹	18 months to five years ³¹	15 to 20 minutes total ³¹
Infant Development Inventory http://childdevrev.com/ specialiststools	No ¹⁵	85 ³¹	75 to 85 ^{15,27,31}	70 to 77 ^{15,27,31}	Up to 18 months ³¹	Five to 10 minutes total ³¹
Parents' Evaluation of Developmental Status http://www.pedstest.com	Yes ¹⁵	10 ^{13,32}	74 to 80 ^{27,30}	70 to 80 ^{27,30}	Birth to seven years and 11 months ³²	Two minutes total ³²
* Stony Brook Medic	ine	Ages	ASQ & Stages	https://www.aafp.c	org/pubs/afp/issues/2017	//0701/p36.html

Questionnaires

Ages and Stages Questionnaire (ASQ-3): Examples for 12 Months

FINE MOTOR

- 1. After one or two tries, does your baby pick up a piece of string with his first finger and thumb? (*The string may be attached to a toy.*)
- 2. Does your baby pick up a crumb or Cheerio with the *tips* of her thumb and a finger? She may rest her arm or hand on the table while doing it.
- 3. Does your baby put a small toy down, without dropping it, and then take his hand off the toy?



YES

SOMETIMES

NOT YET



Why Does It Matter?

- Minimal studies addressing outcomes of pregnancies exposed to MOUD
 - MOUD may have short-term and long-term developmental sequelae on neonates into their childhood
 - Type of MOUD could influence developmental milestones
- Tracking of these milestones gives us more information to improve pregnancy and newborn care

```
Prenatal exposure to methadone or
buprenorphine: Early childhood
developmental outcomes
```

<u>Karol Kaltenbach</u>^a ⊠, <u>Kevin E. O'Grady</u>^b ⊠, <u>Sarah H. Heil</u>^c ⊠, <u>Amy L. Salisbury</u>^{d e f} ⊠, <u>Mara G. Coyle</u>^e ⊠, <u>Gabriele Fischer</u>^g ⊠, <u>Peter R Martin</u>^h ⊠, <u>Susan Stine</u>ⁱ ⊠, <u>Hendrée E. Jones</u>^{j k} 2 ⊠

> Growth and developmental outcome of infants with *inutero* exposure to methadone vs buprenorphine

J B Bier [™], <u>A S Finger</u>, <u>B A Bier</u>, <u>T A Johnson</u> & <u>M G Coyle</u>

Journal of Perinatology **35**, 656–659 (2015) Cite this article





Primary: To assess differences between developmental milestones in infants with in-utero exposure to buprenorphine versus methadone at 2 months - 18 months of age

Secondary: To assess well infant visit compliance across groups



Study Design

- Retrospective cohort study
 - Delivered: January 2017 to December 2021
 - Infant Data through July 2023
- Inclusion criteria:
 - Patients on buprenorphine or methadone antenatally for the indication of OUD
 - Data available on maternal and neonatal outcomes
 - Delivery at Stony Brook University Hospital



Study Design

Maternal Demographics

Perinatal Outcomes type, prenatal visit compliance, MOUD and substance use
Gestational age at delivery, preterm birth rates, mode of delivery, pregnancy inducted hypertension, FGR, gestational

diabetes, delivery complications

• Parity, race/ethnicity, medical

co-morbidities, psychiatric history, BMI, age, insurance Statistical analysis

 Chi square test, student t-tests, and nonparametric tests as appropriate

Significance level < 0.05


Neonatal Outcomes Birth weight, birth weight category, Apgar score, NICU admission, NOWS, NOWS treatment, infant hospital length of stay

(e.g., PPH, transfusion)



Study Design

Developmental data was collected at multiple infant wellness visits










Table 1: Maternal Characteristics Across Buprenorphine and Methadone Groups **Buprenorphine** Methadone p-value (n=125) (n = 38)Nulliparity 44(35.2%) 15(39.5%) 0.63 1st trimester initiation of prenatal 73 (64.6%) 17 (48.6%) 0.09 care (PNC) Number of PNC visits 9.8 (±3.6) 7.8 (±3.1) <0.01 Government Assisted Insurance 108 (88.5%) 35 (92.1%) 0.76 0.21 Any Co-morbidity 24 (19.4%) 4 (10.5%) 116 (92.8%) 37 (97.4%) 0.46 White Race BMI (kg/m^2) 30.6 (±5.5) 28.1 (±7.3) 0.64 Obesity (BMI \geq 30 kg/m²) 20 (22.5%) 6 (22.2%) 0.98 Age (yrs) 30.6 (±4.4) 31.2 (±5.3) 0.49 AMA (\geq 35 yrs) 23 (18.5%) 10 (27.0%) 0.26 Psychiatric diagnosis 89 (71.2%) 26 (68.4%) 0.74 Psychiatric medication use 62 (49.6%) 10 (26.3%) 0.01


Table 2: Perinatal Outcomes Across Buprenorphine and Methadone Groups

	• •		-
	Buprenorphine (n=125)	Methadone (n= 38)	p-value
Pregnancy induced hypertension	18 (14.4%)	6 (16.2%)	0.79
Gestational diabetes	6 (4.8%)	1 (2.7%)	0.58
Fetal Growth Restriction	6 (4.8%)	2 (5.3%)	0.91
Any OB complication	11 (8.8%)	4 (10.5%)	0.75
Gestational age at delivery (wks)	38.2 (±2.7)	37.4 (±3.1)	0.11
PTB <37 weeks	14 (11.2%)	8 (21.1%)	0.12
Cesarean Delivery	57 (45.6%)	19 (50.0%)	0.63
Birth weight (g)	3003.8 (±595.4)	2703.6 (±628.5)	<0.01
Neonatal Opioid Withdrawal Syndrome	98 (80.3%)	32 (86.5%)	0.40
NOWS requiring morphine	25 (20.0%)	16 (42.1%)	<0.01
NICU Admission	80 (64.5%)	26 (70.3%)	0.52
Infant hospital LOS (days)	13.2 (±25.8)	15.9 (±17.4)	0.55
Maternal postpartum visit compliance	69 (55.2%)	15 (13.2%)	0.09
Relapse postpartum	5 (4.3%)	3 (9.1%)	0.38


	Buprenorphine (n=125)	Methadone (n=38)	p-value
2 month (n=132)	0	0	1.00
4 month (n=123)	4 (4.2%)	3 (10.7%)	0.19
6 month (n=112)	1 (1.1%)	2 (8.3%)	0.12
9 month (n=96)	15 (20.0%)	6 (28.6%)	0.39
12 month (n=113)	9 (10.1%)	5 (20.8%)	0.17
18 month (n=101)	23 (29.5%)	6 (26.1%)	0.75

Table 3: Comparison of ANY noted Developmental Delay at Infant Wellness Visits Across Groups


Infant Well Visit Compliance




Developmental Delays 4 month Infant Well Visit




Developmental Delays 6 month Infant Well Visit



Developmental Delays 9 month Infant Well Visit



Developmental Delays 18 month Infant Well Visit





Conclusions

- When comparing outcomes of gestations exposed to methadone and buprenorphine:
 - Similar developmental outcomes to 18 months
 - Possible cognitive delay at the 18-month mark with methadone
 - Similar newborn visit compliance



Discussion

- Stratifies developmental outcomes individually at multiple time points:
 - 2, 4, 6, 9, 12, and 18-month wellness visits
- Standardized developmental milestone assessment at one institution
- Assesses visit compliance at multiple time points

- Confounding social and environmental factors
- Variance in attendance at prenatal visits, may impact the metrics studied
- Does not take into account dose response
- Small number of patients in methadone group

Limitations

Summary

- Developmental milestones did not differ between buprenorphine and methadone groups, except for a small difference in cognitive delay at 18 months
- Long-term outcomes of infants exposed to different MOUD agents in-utero should be assessed through larger studies with a longer follow-up period



Acknowledgements

Co-authors:

Maternal Opioid Management Support Team:

Emily Stetler MD Lauren Stewart MD Oladunni Ogundipe MD Julia Kim MD Rakasa Pattanaik David Garry DO Kimberly Herrera MD Diana Garretto MD Cassandra Heiselman DO

OBGYN

- David Garry DO
- Diana Garretto MD
- Kimberly Herrera MD
- Cassandra Heiselman DO
- Nancy Bowden CNM PMHNP
- Kristen Alarcon NP
- Nursing
 - Wanda Davila RNC
 - Sabine Sterlin RNC
 - Wanda Ivette Davila RNC
 - Susan Little RNC RN, WHNP, NEA-BC
 - Kaitlin M Scherer RN
 - Antonietta Lynch RNC
 - Elizabeth C Mullady RNC
- Regional Perinatal Center
 - Marianna Lawrence RN
 - Keisha M. Butler
 - AnnMarie E Kotarba RNC

- Social work
 - Susan McCarthy LCSW, MS, CCM
 - Zarie Lisa Sedigh LMSW
 - Stephanie Rued LMSW
 - Fatima M Calle LMSW
- IT Support
 - Mindy G Lawrence RN
- Inpatient pharmacy
 - Marie Varela PharmD
- Outpatient office
 - Nichole Seda
- Anesthesia
 - Irina Lokshina MD
- Pediatrics
 - Lisa Clark DNP CPNP-AC/PC
 - Shanthy Sridhar MD FAAP



Additional Slides



Psychiatric Medication Usage Between Groups

	Buprenorphine (n=125)	Methadone (n=38)	p-value
Fluoxetine (Prozac)	5 (4.0%)	0 (0.0%)	0.59
Alprazolam (Xanax)	11 (8.8%)	4 (10.5%)	0.75
Venlafaxine (Effexor)	0 (0%)	1 (2.6%)	0.23
Sertraline (Zoloft)	15 (12.0%)	2 (5.3%)	0.36
Escitalopram (Lexapro)	5 (4.0%)	1 (2.6%)	1.00
Bupropion (Wellbutrin)	4 (3.2%)	2 (5.3%)	0.62
Gabapentin (Neurontin)	11 (8.8%)	3 (7.9%)	1.00
Duloxetine (Cymbalta)	2 (1.6%)	0 (0.0%)	1.00
Buspirone (Buspar)	4 (3.2%)	1 (2.6%)	1.00
Quetiapine (Seroquel)	9 (7.2%)	1 (2.6%)	0.46
Clonazepam (Klonopin)	7 (5.6%)	0 (0.0%)	0.20
Lamotrigine (Lamictal)	3 (2.4%)	0 (0.0%)	1.00
Citalopram (Celexa)	3 (2.4%)	0 (0.0%)	1.00
Other	20 (16.0%)	2 (5.3%)	0.09
ANY Psych Meds	62 (49.6%)	10 (26.3%)	0.01

Buprenorphine Dosing at Delivery & Developmental Delay

	High Dose (>16mg)	Р	Higher Dose (>12mg)	Р
Any delay at 4 months	2 (15.4%)	0.09	2 (6.1%)	0.61
Any delay at 6 months	0 (0.0%)	1.00	0 (0.0%)	1.00
Any delay at 9 months	3 (42.9%)	0.15	6 (25.0%)	0.55
Any delay at 12 months	1 (9.1%)	1.00	5 (15.6%)	0.28
Any delay at 18 months	3 (37.5%)	0.69	10 (38.5%)	0.26
Cumulative delay at 12 months	5 (35.7%)	0.14	10 (24.4%)	0.30
Cumulative delay at 18 months	7 (50.0%)	0.22	19 (45.2%)	0.04

Range of Buprenorphine dose at delivery

- 0.5 mg to 30 mg
- Median 10mg
- Mean 11 mg
- High does (>16mg) n=15
- Higher dose (>12mg) n=45

Methadone Dosing at Delivery & Developmental Delay

	High Dose (>100mg)		
	Yes	No	— Р
Any delay at 4 months	3 (18.8%)	0 (0.0%)	0.24
Any delay at 6 months	2 (15.4%)	0 (0.0%)	0.48
Any delay at 9 months	4 (44.4%)	2 (16.7%)	0.33
Any delay at 12 months	3 (25%)	2 (16.7%)	1.00
Any delay at 18 months	3 (27.3%)	3 (25%)	0.90
Cumulative delay at 12 months	6 (30.0%)	4 (28.6%)	0.93
Cumulative delay at 18 months	8 (38.1%)	6 (35.3%)	0.86

Range of Methadone dose at delivery

- 20mg to 220mg
- Median 110mg
- Mean 106mg
- High dose (>100mg) n=21

Infant Developmental Delays 2 months through 6 months

	Buprenorphine (n=125)	Methadone (n=38)	p-value
2 month wellness visit (n=132)			
Any delay	0	0	1.00
4 month wellness visit (n=123)			
Any delay	4 (4.2%)	3 (10.7%)	0.19
Social Emotional Delay	1	0	1.00
Language Communication Delay	0	1	0.23
Cognitive Delay	1	1	0.41
Movement Physical Delay	3	3	0.31
6 month wellness visit (n=112)			
Any delay	1 (1.1%)	2 (8.3%)	0.12
Social Emotional Delay	0	0	1.00
Language Communication Delay	0	2	0.05
Cognitive Delay	0	1	0.21
Movement Physical Delay	1	1	0.38



Infant Developmental Delays 9 months through 18 months

	Buprenorphine (n=125)	Methadone (n=38)	p-value	
9 month wellness visit (n=96)				
Any delay	15 (20.0%)	6 (28.6%)	0.39	
Social Emotional Delay	2	0	1.00	
Language Communication Delay	3	2	0.30	
Cognitive Delay	3	1	1.00	
Movement Physical Delay	13	5	0.53	
12 month wellness visit (n=113)				
Any delay	9 (10.1%)	5 (20.8%)	0.17	
Social Emotional Delay	3	0	1.00	
Language Communication Delay	5	3	0.36	
Cognitive Delay	5	3	0.36	
Movement Physical Delay	5	3	0.36	
Any delay at any wellness visit up to 12 months	22 (19.0%)	10 (29.4%)	0.19	
18 month wellness visit (n=101)				
Any delay	23 (29.5%)	6 (26.1%)	0.75	
Social Emotional Delay	3	3	0.13	
Language Communication Delay	21	6	1.00	
Cognitive Delay	2	4	0.02	
Movement Physical Delay	3	3	0.13	

